Skip to main content

FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma

Clinical and Translational Oncology volume 19, pages 265–268 (2017)Cite this article

Abstract

Background

Up to date, there are no data about FGFR2 expression and its predictive role in papillary RCC (pRCC) patients. The aim of the present study was to test FGFR2 expression and mutations for association with survival outcome in patients with pRCC.

Methods

Specimens of removed primary tumors from 214 untreated metastatic pRCC patients were evaluated by immunohistochemistry with FGFR2 antibody. FGFR2 mutations were assessed by PCR and direct sequencing, with DNA obtained from 62 paraffin-embedded pRCC samples. FGFR2 expression was tested for associations with progression-free survival (PFS), overall survival (OS) and best objective response.

Results

Expression of FGFR2 was observed in 23 % (49/214) of primary pRCC, mostly in cytoplasm of tumor cells. Expression of FGFR2 was significant lower in normal tissue of kidney (1 %, P = 0.001). FGFR2 S252W mutation was found in one patient (1.6 %), and no N549K mutation was detected. FGFR2 expression was strongly associated with a number of metastatic sites, type 2 of pRCC, lower nucleolar grade (P < 0.001). FGFR2-positive patients had significantly shorter OS and PFS (P < 0.05). On multivariate analysis, FGFR2 expression, MSKCC risk group and type of pRCC were found to be independent predictors of survival.

Conclusions

In this study, we described immunohistochemical expression of FGFR2 in a large series of pRCC specimens. FGFR2 expression was found to be prognostic factor for survival in patients with metastatic pRCC. FGFR2 mutations are rare across papillary types of RCC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol. 2015;10:423–7.

    Article  PubMed  Google Scholar 

  2. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000.

    CAS  Article  PubMed  Google Scholar 

  4. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10:77–83.

    Article  PubMed  Google Scholar 

  5. Tsimafeyeu I, Bratslavsky G. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma. Oncology. 2015;88:321–31.

    CAS  Article  PubMed  Google Scholar 

  6. Tsimafeyeu I, Demidov L, Ta H, Stepanova E, Wynn N. Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol. 2010;28(15 suppl):4621.

    Google Scholar 

  7. Eble JN, Sauter G, Epstein JI. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization classification of tumours. Lyon: IARC Press; 2004. p. 7–37.

    Google Scholar 

  8. Courthod G, Tucci M, Di Maio M, Scagliotti GV. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96:100–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Terry Fox Foundation and Mr. Sergey Kartashov.

Author information

Affiliations

  1. Kidney Cancer Research Bureau, Bazovskaya ul. 4/1 of. 15, Moscow, 125635, Russia

    I. Tsimafeyeu & A. Naumova

  2. Tatarstan Regional Cancer Center, Kazan, Russia

    A. Khasanova & M. Gordiev

  3. N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

    E. Stepanova, D. Khochenkov, A. Snegovoy & L. Demidov

  4. Altai Regional Cancer Center, Barnaul, Russia

    I. Varlamov

Authors
  1. I. Tsimafeyeu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Khasanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Stepanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Gordiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Khochenkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Naumova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Varlamov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Snegovoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Demidov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Tsimafeyeu.

Ethics declarations

Conflict of interest

Authors have no financial relationship.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tsimafeyeu, I., Khasanova, A., Stepanova, E. et al. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. Clin Transl Oncol 19, 265–268 (2017). https://doi.org/10.1007/s12094-016-1524-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-016-1524-y

Keywords

  • FGFR2
  • Overexpression
  • Mutations
  • Papillary renal cell carcinoma
  • Overall survival